EP
RARE icon

Essential Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Essential Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53K Buy
1,587
+619
+64% +$15.4K 0.02% 592
2026
Q1 		$20.3K Sell
968
-728
-43% -$16.4K 0.01% 920
2025
Q4 		$39K Buy
1,696
+1,607
+1,806% +$52.8K 0.01% 677
2025
Q3 		$2.68K Buy
+89
New +$2.67K ﹤0.01% 1695

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Essential Partners's RARE Position: Q2 2026 in Review

Essential Partners increased its Ultragenyx Pharmaceutical (RARE) stake by 64% in Q2 2026, buying an estimated $15.4K and bringing the position to 1,587 shares worth $53K. The position accounts for 0.02% of the portfolio, ranked #592.

Essential Partners first reported a position in RARE in Q3 2025 and has held it in 4 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Essential Partners held 1,587 shares of Ultragenyx Pharmaceutical worth $53K as of Q2 2026.
  • Essential Partners bought 619 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $15.4K.
  • Ultragenyx Pharmaceutical made up 0.02% of Essential Partners's portfolio in Q2 2026, its #592 holding.
  • Essential Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and has held it in 4 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.